TScan Therapeutics, Inc. (TCRX:NASDAQ) closed at $0.203 on October 23, 2026, down 6.01% on the day. The stock trades 91.6% below its 52-week high of $2.43 and 1.1% above its 52-week low of $0.201. Over the past year, it lost 91.2%. TScan Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, TCRX closed higher on 105 days (42%). Its best day was April 20, 2026 (+20.17%) and its worst was September 2, 2026 (-42.79%). The stock moved 10% or more in a single session 18 times. It opened at least 5% above the previous day's high 2 times.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Find more stocks like TCRX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.